Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease.
Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, Faust J, Fuchs P, Sens B, Neubert K, et al. Int Immunopharmacol. 2006 Dec 20; 6(13-14):1925-34. Epub 2006 Oct 17.